Overview

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Status:
Completed

Trial end date:
2020-02-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of 2 dose regimens of imetelstat in participants with intermediate-2 or high-risk myelofibrosis (MF) whose disease is relapsed after or is refractory to Janus Kinase (JAK) inhibitor treatment. Key secondary endpoint includes overall survival.

Phase:

Phase 2

Details

Lead Sponsor:

Geron Corporation
Janssen Research & Development, LLC

Treatments:

Imetelstat
Motesanib diphosphate
Niacinamide